Tumour Budding with Epithelial Mesenchymal Transition Markers - A Novel Prognostic Tool for Breast Carcinoma

肿瘤出芽与上皮间质转化标志物——乳腺癌的一种新型预后工具

阅读:1

Abstract

INTRODUCTION: Breast cancer is a leading cause of cancer-related deaths among women worldwide. Prior to metastasis, carcinomas undergo epithelial-mesenchymal transition (EMT), a process wherein cancer cells acquire mobility, form tumor buds (TBs), and invade the stroma. The presence and number of TBs are directly proportional to tumor invasion and metastasis. By scoring TBs and using immunohistochemistry (IHC) to detect EMT process, we can identify patients with poor prognosis after surgical resection. This enables early recognition of patients requiring aggressive treatment and follow-up. AIM: The aim of this study was to propose an algorithm for measuring TB and to establish the correlation between TB with EMT markers expression and main clinical parameters. MATERIALS AND METHODS: A retrospective analytical study in an urban tertiary health care center involving 47 cases of invasive breast carcinomas. TB was assessed in Haematoxylin & Eosin stained tissue sections followed by IHC with EMT markers. Association between TB, EMT markers, and main clinical parameters was statistically analyzed using the Chi-square test. RESULTS: Among 47 cases, 30 had mean-low TB score (≤4/ 10HPF) and 17 had mean-high TB score (>4/10 HPF). Tumors with high TB scoring showed strong SNAIL, TWIST, and N-cadherin expression. Tumors with low TB scores showed high E-cadherin expression and low SNAIL, TWIST, and N-cadherin expression. CONCLUSION: The study established a positive correlation between TB and EMT markers. High TB scores are significantly associated with lymphovascular invasion, lymph node metastasis, and higher tumor grading. Using TB score and EMT markers in breast cancer management can facilitate patient-centered approach.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。